If you wonder whether knowing about a placebo destroys its effect, the answer isn’t a simple yes or no — these 8 findings show where changes appeared and where the evidence stopped

You see “placebo” on the label and wonder whether any effect can remain once you know. Can a treatment described as a placebo still change how you feel?

Yes, it can for some people and some symptoms. The effect does not appear in every person, outcome, or study.

Randomized trials and a 2025 systematic review report effects in clinical and non-clinical groups. The review found stronger results when people rated their own symptoms.

That distinction matters. Pain, fatigue, distress, and anxiety can shift without proving that a disease changed or that every body measure moved with them.

The 8 parts of this explainer separate those claims. They cover what researchers measured, where results appeared, and where the findings stopped.

Before the sections open, the figures this page stands on — each one carrying its own source.

What an open-label placebo means

Your first health question starts with the label itself. In these studies, participants knew they had received a placebo.

That disclosure separates open-label treatment from a deceptive placebo. The research asks whether an effect can remain without hiding the placebo label.

Knowing about the placebo does not settle the result

For the reader holding that knowledge, disbelief can seem like the end of the story. Several trials found measurable changes despite full disclosure.

Those changes do not mean every participant responded. One pain study found a substantial response in 40.6% of participants.

The same study found that 59.4% did not respond. Open labeling therefore allows an effect without making that effect reliable for everyone.

A person may also improve during a study for reasons beyond the placebo. Symptoms can change over time, and other care may continue.

The comparison group changes what improvement means

Your reading of an effect depends on what the placebo group faced. Studies have compared open-label placebos with no treatment, usual care, or another placebo condition.

Improvement from the starting point answers one question. A larger change than the comparison group answers a stronger and different question.

An allergic rhinitis trial showed why this matters. Symptoms fell in every treatment group after two weeks.

The open-label placebo added no effect over treatment as usual. Improvement alone could not show that the placebo caused the change.

A planned allergic rhinitis study used four groups to separate probiotic treatment, blinded placebo, open-label placebo, and spontaneous symptom changes. That design targets several possible explanations.

Which open-label placebo effects have been measured

The effect a reader hopes to understand may involve pain, fatigue, distress, anxiety, or daily function. Trials have not treated those outcomes as one thing.

Researchers measured symptoms in clinical groups and feelings in healthy groups. Some studies also included movement, medication use, or brain activity.

Pain, fatigue, and bowel symptoms

Someone living with symptoms will notice the range first. Open-label placebo trials cover chronic back pain, knee pain, acute pain, cancer-related fatigue, and IBS.

A chronic back pain trial reported pain reductions of 1.5 in the open-label group and 0.2 with treatment as usual. The groups changed by different amounts.

Another trial among Japanese patients found no significant group differences at week 3. Pain scores, disability scores, and timed movement did not separate the groups.

For IBS, one trial recorded greater mean improvement with open-label placebo than with no-pill control. The scores improved by 90.6 versus 52.3.

An earlier IBS trial also found lower symptom severity and more adequate relief. Its quality-of-life result only showed a trend at the 21-day endpoint.

Stress, test anxiety, and emotional distress

A reader focused on mental strain finds a similar mix. Several studies report changes in feelings, yet they use different tasks and settings.

Healthy medical students used an open-label placebo for 21 days during midterm exams. They reported gains in stress, fatigue, confusion, and overall well-being.

Another trial found better test anxiety and self-management results after two weeks. A separate study also recorded a significant group-by-time pattern for test anxiety.

Emotional distress has changed during open-label placebo research as well. One experiment linked reduced distress with activity in several brain regions.

These results support a possible effect on felt experience. They do not turn every stress result into proof of lasting mental health change.

A side-by-side view keeps the outcome, comparison, and result tied together. That prevents one positive finding from standing in for the whole field.

What follows rests on a handful of cited figures. Here they are, receipts attached.

Why self-reported effects matter most

Your own symptom rating can capture pain or fatigue that an outside observer cannot see. It also depends on attention, memory, context, and judgment.

The 2025 review found open-label placebos effective across clinical and non-clinical samples. Effects appeared strongest when researchers used self-reports.

A symptom report remains a real measurement

For a reader in pain, a reported change can matter in daily life. Personal ratings provide the direct measure for experiences such as pain and distress.

Calling an outcome subjective does not make it false. It describes who judged the change and how researchers recorded it.

Still, a self-report cannot prove that tissue, disease activity, or physical function changed. Those claims require measures aimed at those exact outcomes.

Back pain research shows the wider range of measures. One trial included disability, spine movement, depression, anxiety, and stress alongside pain.

The cited result does not establish that every measure improved. Each outcome needs its own reported comparison.

Objective measures answer a different question

To confirm what you feel, you may look to a scan, movement test, or medication count. Each measure captures a different part of the response.

Brain activity can change during a task while symptoms remain the main clinical outcome. Movement can stay similar even when pain ratings shift.

One facial-expression study found lower LPP amplitudes from 1000–6000 ms after open-label placebo use. The change appeared while participants viewed angry expressions.

That finding concerns neural processing during a set task. It does not establish a broad change in mood, health, or behavior.

Medication use offers another kind of outcome. Conditioned open-label placebo reduced total opioid use in a pilot pain study by the intervention’s end.

After spine surgery, daily worst pain also fell by −1.0 point on the 10-point scale. Average daily pain did not show a significant group difference.

A page should show what it grows from. Here is the tree — every leaf quoted, every receipt attached.

What pain studies show

Pain may bring the reader closest to trying an open-label placebo. The evidence includes positive findings, no group differences, and uneven response.

No single pain result represents all pain conditions. Chronic back pain, knee osteoarthritis, induced heat pain, and surgery involve different settings.

Some trials found lower pain ratings

For someone tracking daily pain, several findings look meaningful. A knee osteoarthritis trial recorded lower daily pain in open-label groups than with no treatment.

The reported comparison reached p = 0.013 with d = 0.64. Two different placebo explanations produced no meaningful difference from each other.

Healthy adult males rated induced acute pain 21% lower during placebo treatment than during no treatment. Median ratings measured 4.0 versus 5.1.

A heat pain trial found lower intensity and unpleasantness when participants received a placebo rationale. The result points toward the explanation given with treatment.

Chronic back pain has also shown short-term change. One injection study reported reduced pain intensity after treatment compared with usual care.

Other pain trials found limited or absent differences

The reader also faces evidence that does not confirm an added effect. A Japanese back pain trial found no significant difference between groups at week 3.

Its pain result reached p = 0.19. Disability reached p = 0.40, while timed movement reached p = 0.98.

Response can also split sharply within one study. The naloxone experiment recorded substantial responses in 40.6% and no response in 59.4%.

Naloxone blocked the reported open-label placebo analgesia in that experiment. This result supports opioid-system involvement under those study conditions.

It does not prove that every open-label effect uses the same pathway. Fatigue, distress, and bowel symptoms may involve different processes.

The mixed pain record supports a narrow conclusion. Open-label placebos can affect pain ratings, while response varies across people, methods, and settings.

Effects beyond pain

A reader dealing with fatigue, IBS, hot flushes, or test stress needs evidence from that same problem. Pain findings cannot answer every symptom question.

Trials outside pain provide useful signals. They also show why the exact outcome and comparison still matter.

Cancer-related fatigue and IBS

For someone facing cancer-related fatigue, open-label placebo research recorded changes in tiredness and disrupted quality of life. Those studies focused on symptom relief.

In one trial, participants who later chose 21 days of open-label placebo reported reductions of 23% in fatigue severity and 35% in disrupted quality of life.

Another advanced cancer trial found significant fatigue improvement on days 15 and 29. At those points, all participants received open-label placebo.

The groups showed no difference from each other then. That result supports improvement during treatment without proving one arm outperformed the other.

IBS studies offer stronger group comparisons. Open-label placebo improved symptom scores more than a no-pill condition in one randomized trial.

Earlier IBS work also favored open-label placebo for symptom severity and adequate relief. Quality of life showed only a trend at the 21-day endpoint.

Hot flushes, allergies, and exam stress

A reader comparing symptoms should expect different findings across conditions. Similar treatment labels do not guarantee similar effects.

For menopausal hot flushes, taking placebos for 8 weeks produced no difference from taking them for 4 weeks. Longer use did not improve that comparison.

Remote open-label placebo treatment for allergic rhinitis also added no benefit over usual care. Every group improved from baseline after two weeks.

Exam stress studies produced more positive results. Students reported improved test anxiety, self-management, stress, fatigue, confusion, or well-being.

Those studies involved healthy students during exams. Their findings do not establish treatment effects for a diagnosed anxiety disorder.

The condition remains part of the claim. Evidence for one symptom should stay attached to that symptom, setting, and measured period.

You have read enough about minds in general. This one maps yours — drawn live from your answers, with a citation under every claim.

How expectation and the treatment explanation shape results

Your expectations may shift after someone explains why an open-label placebo could help. Research suggests that shift can matter to the result.

A 2023 network meta-analysis found positive treatment expectations important for open-label placebos to work. Expectation therefore belongs inside the evidence, not outside it.

The rationale can change the response

For the reader hearing an explanation, the words around treatment may shape what follows. A heat pain study tested this directly.

Groups given a placebo rationale reported less pain intensity and unpleasantness than the open-placebo group without that rationale. The measured effects reached d = 0.43 and d = 0.49.

This result does not show that explanation alone produces every effect. It shows that the rationale changed outcomes in that experiment.

Researchers have raised broader concerns about separating the pill, the explanation, and the clinical interaction. Weak comparisons can blur those parts.

A placebo trial therefore studies a treatment setting as well as a labeled pill. Design choices influence what the final comparison can establish.

Acceptance does not guarantee improvement

A reader may accept the idea of an open-label placebo and still feel no change. Belief, hope, and response do not line up perfectly.

Qualitative research found acceptance depended on whether patients thought the treatment could solve their problem. Doubts about effectiveness and perceived risks also mattered.

Participants who improved offered several explanations for the change. Open-label recipients credited the treatment itself less often than blinded placebo recipients.

That response makes sense within the design. People who know about the placebo can notice improvement without deciding that the placebo caused it.

Outcome expectations may support an effect, yet they cannot predict each person’s result. The 40.6% response finding shows how sharply outcomes can differ.

Expectation works best as one tested factor. It should not become a claim that every symptom comes from belief.

Remember the note you left? It has been waiting for you.

What brain findings do and do not establish

A reader may look to brain findings for proof that the effect feels real. The studies record associations and task-based changes, not a complete cause.

Two cited experiments connect open-label placebo responses with neural measures. Each examined a specific experience under set study conditions.

Emotional distress and brain activity

During emotional distress, the reader’s main concern remains the felt change. One study found reduced distress alongside activity in several brain regions.

Those regions included the periaqueductal gray, bilateral anterior hippocampi, and anterior cingulate cortex. Researchers described them as areas known to shape emotional states.

The finding links lower distress with recorded brain activity. An association cannot show that one region produced the whole response.

Nor does it establish a permanent change. The cited result concerns the measured study period and the task used there.

Brain data add a second kind of measure to the symptom report. They do not replace the participant’s account or widen the claim beyond distress.

Responses to angry faces

For a reader viewing emotional signals, one experiment offers a narrower result. Open-label placebo use changed processing of angry facial expressions.

The study found reduced LPP amplitudes from 1000–6000 ms across a frontal cluster. That measure came from responses to anger expressions.

Such a result says little by itself about daily conflict, mood, or mental health. Those outcomes were outside the stated finding.

Neural measures can support the presence of a response under controlled conditions. They cannot prove one shared mechanism across pain, fatigue, IBS, and anxiety.

Naloxone results add another clue for pain. Blocking analgesia in one experiment suggests an opioid-related pathway for that response.

The most careful reading keeps each clue local. Brain activity, pain blockade, expectation, and symptom reports answer related yet separate questions.

If any of this pressed on something tender, the help below is real and free, there whenever you need it.

One last move before the close: press this page into a single sentence of your own — the when and the how, decided now.

In the same open spirit as the receipts above: here is how the page was built, device by device.

If part of your situation reaches past this page, the guides below cover the next step directly.

How long open-label placebo effects last

Your final health concern may involve duration. Short-term improvement does not tell you what remains years later.

Long follow-up findings appear mixed because the studies used different groups and comparisons. Their results should not be merged into one promise.

Two long-term back pain findings look different

For a reader with chronic back pain, one 3-year follow-up found no outcome differences between groups. Earlier open-label treatment left no group advantage.

A separate 5-year follow-up reported that improvements persisted. Medication use also fell from 87% to 38% compared with baseline.

Reported analgesic use moved from 80% to 31%. Antidepressant use moved from 24% to 11%, while benzodiazepine use moved from 15% to 5%.

Those findings use baseline change, while the 3-year study reports differences between groups. The comparison target changes the meaning.

Neither result can erase the other. Together, they show why lasting improvement and lasting placebo advantage remain different claims.

The clearest answer from the full record

A reader can leave with a firm answer and a firm limit. Open-label placebo effects can occur even when participants know about the placebo.

The clearest evidence concerns self-reported outcomes. Trials record changes in pain, fatigue, IBS symptoms, test anxiety, stress, and emotional distress.

Results vary across studies. Some show an advantage over a comparison group, while others show improvement without an added placebo effect.

Positive expectations appear important. The explanation given with treatment can also change pain responses under tested conditions.

Brain and drug-blocking studies offer clues about possible processes. They do not establish one mechanism for every open-label placebo effect.

Long-term evidence also resists a simple promise. One follow-up found no group difference, while another recorded gains compared with baseline.

The useful conclusion stays specific. An open label does not erase every placebo response, though it never guarantees one.

Common questions can keep the strongest claims apart from the limits. Each answer ties the conclusion to the outcome that researchers actually measured.

This is general information about the mind, not therapy or a diagnosis. If things feel hard, please consult a professional. In a crisis, reach a free, confidential crisis hotline right away; findahelpline.com lists one for your country.